We are a leading cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Our goal is to become the premier cell analysis company through continued innovation that facilitates scientific advances in biomedical research and clinical applications. We believe our core instruments, the Aurora and Northern Lights systems, are the first full spectrum flow cytometers able to deliver high-resolution, high-content and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells (“Full Spectrum Profiling” or “FSP”). Our novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with exquisite sensitivity. 

Wenbin Jiang, Ph.D., a co-founder of our company, has served as the CEO and a member of our board of directors since December 2014. In 1998, Dr. Jiang co-founded E2O Communications, Inc., a fiber optic subsystems manufacturing company, which was acquired by JDS Uniphase Corp. in 2004. Dr. Jiang is an inventor with more than 95 U.S. patents. He earned his Ph.D. in electrical engineering from the University of California, Santa Barbara.

(Note: Cytek BioSciences upsized its IPO at pricing on July 22, 2021, to sell 16.75 million shares – up from 14.6 million shares in the prospectus – and priced the IPO at $17 – the mid-point of its $16-to-$18 range.)